RVTY vs TWST: Revvity and Twist Bioscience compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- Revvity is the larger company, worth $17.3B, about 1.8 times Twist Bioscience.
- Twist Bioscience grew revenue faster over the last year (+23.2% vs +1.3%).
- Revvity keeps more of each dollar of revenue as operating profit (12.3% vs -33.6%).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | RVTY | TWST |
|---|---|---|
| Market cap | $17.3B | $9.8B |
| Share price | $154.18 | $159.78 |
| Revenue (last fiscal year) | $2.9B | $377M |
| Free cash flow (last fiscal year) | $509M | -$76M |
| Revenue growth, last year | +1.3% | +23.2% |
| Revenue growth per year, last 5 fiscal years | -13.4% | +29.9% |
| Operating margin | 12.3% | -33.6% |
| Net margin | 8.2% | -31.7% |
| Return on equity | 3.3% | -30.7% |
| P/E (trailing) | 74.5x | — |
| Price / free cash flow | 34.0x | — |
| EV / EBITDA | 25.6x | — |
| FCF growth the price implies | 11.9% | — |
| Dividend yield | 0.18% | — |
| Debt / equity | 0.67x | 0.51x |
| Fundamental grade | D | F |
| Superinvestors holding it | 4 | 3 |
| Insider purchases, last 12 months | 0 | 0 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Revvity
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $5.1B | $1.3B | 26.3% |
| 2022 | $3.3B | $594M | 22.4% |
| 2023 | $2.8B | $10M | 10.9% |
| 2024 | $2.8B | $542M | 12.6% |
| 2025 | $2.9B | $509M | 12.5% |
Twist Bioscience
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $132M | -$139M | -115.4% |
| 2022 | $204M | -$226M | -115.3% |
| 2023 | $245M | -$170M | -88.6% |
| 2024 | $313M | -$69M | -70.6% |
| 2025 | $377M | -$76M | -36.2% |
Where the revenue comes from
Revvity · by segments, 2025
Life Sciences$1.4B50%
Diagnostics$1.4B50%
Twist Bioscience · by products, 2025
NGS tools$208M55%
Synthetic genes$114M30%
Antibody discovery$23M6%
Oligo pools$20M5%
DNA libraries$11M3%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open RVTY in InvestinglyQuestions
Which is bigger, Revvity or Twist Bioscience?
Revvity (RVTY), at $17.3B against $9.8B.
Which grows faster, RVTY or TWST?
Twist Bioscience: revenue grew +23.2% over the last year, against +1.3%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.